0001270073 false 0001270073 2021-07-29 2021-07-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549










Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): July 29, 2021




Intercept Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)





(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


10 Hudson Yards, 37th Floor

New York, NY 10001

(Address of Principal Executive Offices and Zip Code)


Registrant’s telephone number, including area code: (646) 747-1000




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ICPT   Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 2.02. Results of Operations and Financial Condition.


On July 29, 2021, Intercept Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2021. A copy of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.


The information in this Item 2.02 and Exhibit 99.1 attached hereto is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.





99.1   Press Release issued July 29, 2021
104   Cover Page Interactive Data File (embedded as Inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



  By:/s/ Andrew Saik
 Name:  Andrew Saik
  Title:Chief Financial Officer


Date: July 29, 2021










99.1   Press Release issued July 29, 2021
104   Cover Page Interactive Data File (embedded as Inline XBRL document)




EX-99.1 2 tm2123441d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1



Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update


Worldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter


Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to $340 million and Non-GAAP adjusted operating expense guidance of $380 to $410 million


Updates to the Ocaliva U.S. Prescribing Information complete


Company provides regulatory update on NASH fibrosis program in the U.S.


Company to host conference call today at 8:30 a.m. ET


NEW YORK, July 29, 2021 – Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended June 30, 2021.


“In the second quarter, we reported double digit sales growth driven by strong business performance both in the U.S. and our International Region and the company achieved its first cash positive quarter. In the U.S., we worked with the FDA to finalize important changes to the Ocaliva Prescribing Information, allowing us to now focus on the long-term growth of our foundational PBC business,” said Jerry Durso, President and Chief Executive Officer of Intercept. “We are executing a comprehensive campaign to educate healthcare providers, patients and other key stakeholders on the updates to the Ocaliva label. Five years after the initial accelerated approval of Ocaliva, there are still many eligible patients who have the potential to benefit from second-line therapy, and we look forward to resuming our long-term strategy of expansion into the community gastroenterology setting in Q3.”


“We continue to make progress on our development program in NASH fibrosis,” Durso continued. “Since the beginning of 2021, we have had frequent exchanges with FDA to gain alignment and feedback on safety, biopsy methodology and efficacy data. We have now gained enough insight from FDA in these critical areas to move forward on our plan, and with the right team in place, we have begun to generate what will ultimately be the largest data package ever produced in the NASH field. We will be evaluating available data internally to inform decision-making and expect that process to continue into the early part of next year, with a goal of holding our pre-submission meeting to review the data with FDA during the first half of 2022. The regulatory review of OCA in the EU remains on pause as we evaluate the potential to include additional data that may support our application. As we continue to advance our regulatory dialogue in NASH fibrosis, we also look forward to delivering the next major Phase 3 data readout in the field with REVERSE, our study evaluating OCA in patients with compensated cirrhosis due to NASH. This is a population with significant unmet need, and we expect topline results by end-of-year. We also continue to make progress on our pipeline programs including our OCA-bezafibrate fixed dose combination in PBC and our next-generation FXR agonist INT-787. We recently initiated first-in-human studies of INT-787 and look forward to sharing additional details about this compound in the future.”





Financial Results



·We recognized $96.6 million in total revenue in the second quarter of 2021, as compared to $77.2 million in total revenue in the prior year quarter. Ocaliva net sales in the second quarter of 2021 were comprised of U.S. net sales of $68.2 million and ex-U.S. net sales of $28.4 million, as compared to U.S. net sales of $59.6 million and ex-U.S. net sales of $17.6 million in the prior year quarter.


Operating Expenses

·In the quarters ended June 30, 2021 and 2020, we recorded $95.8 million and $129.3 million, respectively, in total operating expenses and $86.5 million and $112.4 million, respectively, in non-GAAP adjusted operating expenses, which excludes non-cash stock-based compensation expense of $8.4 million and $16.1 million, respectively, and depreciation expense of $0.9 million and $0.8 million, respectively.


·References in this press release to “non-GAAP adjusted operating expenses” mean our total operating expenses, as calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), adjusted for the effects of two non-cash items: stock-based compensation and depreciation. See “Non-GAAP Financial Measures” below. A reconciliation of non-GAAP adjusted operating expenses to total operating expenses for all historical periods presented is included below under the heading “Reconciliation of Non-GAAP Adjusted Operating Expenses to Total Operating Expenses.”


Cost of Sales

·Our cost of sales was $0.6 million in the second quarter of 2021, as compared to $1.9 million in the prior year quarter. Our cost of sales for the quarters ended June 30, 2021 and 2020 consisted primarily of packaging, labeling, materials and related expenses.


Sales, General & Administrative Expenses

·Our selling, general and administrative expenses were $57.7 million in the second quarter of 2021, down from $93.4 million in the prior year quarter. The decrease was primarily driven by actions taken to decrease expenses relating to launch preparation activities associated with the potential approval and commercialization of OCA for liver fibrosis due to NASH.


Research & Development Expenses

·Our research and development expenses increased to $37.8 million in the second quarter of 2021, up from $34.0 million in the prior year quarter. The increase was primarily driven by the recognition of lower UK R&D tax credit versus the prior year quarter, partially offset by lower NASH development costs.


Interest Expense

·Interest expense in the quarters ended June 30, 2021 and 2020 was $12.6 million and $11.9 million, respectively. For the three months ended June 30, 2021 and 2020, interest expense related to the $230.0 million aggregate principal amount of 2.00% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”) that we issued in May 2019 and the $460.0 million aggregate principal amount of 3.25% Convertible Senior Notes due 2023 (the “2023 Convertible Notes” and together with the 2026 Convertible Notes, the “Convertible Notes”) that we issued in July 2016.





Net Loss

·In the second quarter of 2021 we reported a net loss of $11.1 million, a decrease compared to a net loss of $63.3 million in the second quarter 2020.


Cash Position

·As of June 30, 2021, we had cash, cash equivalents, restricted cash, and investment debt securities available for sale of approximately $422.5 million. As of December 31, 2020, we had cash, cash equivalents, restricted cash, and investment debt securities available for sale of approximately $477.2 million.


2021 Financial Guidance


We are reiterating our full year 2021 worldwide Ocaliva net sales guidance of $325 million to $340 million as we monitor post-label update market dynamics.


We are reiterating our full year 2021 non-GAAP adjusted operating expense guidance of between $380 million to $410 million. 


See “Non-GAAP Financial Measures” below. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.


Conference Call on July 29, 2021 at 8:30 a.m. ET


We are hosting our second quarter 2021 financial results conference call and webcast on July 29, 2021 at 8:30 a.m. ET. The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) passcode 2919379. A replay of the call will be available on our website shortly following the completion of the call and will be available for two weeks.


About Intercept


Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.


Non-GAAP Financial Measures


This press release presents non-GAAP adjusted operating expenses on a historical and projected basis. For the periods presented, non-GAAP adjusted operating expenses exclude from total operating expenses, as calculated and presented in accordance with GAAP, the effects of two non-cash items: stock-based compensation and depreciation. Non-GAAP adjusted operating expenses is a financial measure that has not been prepared in accordance with GAAP. Accordingly, investors should consider non-GAAP adjusted operating expenses in addition to, but not as a substitute for, total operating expenses that we calculate and present in accordance with GAAP. Among other things, our management uses non-GAAP adjusted operating expenses to establish budgets and operational goals and to manage our business. Other companies may define or use this measure in different ways. We believe that the presentation of non-GAAP adjusted operating expenses provides investors and management with helpful supplemental information relating to operating performance and trends. A table reconciling non-GAAP adjusted operating expenses to total operating expenses for all historical periods presented is included below under the heading “Reconciliation of Non-GAAP Adjusted Operating Expenses to Total Operating Expenses”. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.





About Liver Fibrosis due to NASH


Nonalcoholic steatohepatitis (NASH) is a serious progressive liver disease caused by excessive fat accumulation in the liver that induces chronic inflammation, resulting in progressive fibrosis (scarring) that can lead to cirrhosis, eventual liver failure, cancer and death. Advanced fibrosis is associated with a substantially higher risk of liver-related morbidity and mortality in patients with NASH. In the United States, NASH is currently the second leading cause for liver transplantation overall, and in females, the leading cause. NASH is anticipated to become the leading indication for liver transplantation in Europe within the next decade. There are currently no medications approved for the treatment of NASH.


About the REGENERATE Study


REGENERATE is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study assessing the safety and efficacy of obeticholic acid (OCA) on clinical outcomes in patients with liver fibrosis due to NASH. A pre-specified 18-month analysis was conducted to assess the effect of OCA on liver histology comparing month 18 biopsies with baseline. REGENERATE has completed target enrollment for the clinical outcomes cohort, with 2,480 adult NASH patients randomized at over 300 qualified centers worldwide, and is expected to continue through clinical outcomes for verification and description of clinical benefit. The end-of-study analysis will evaluate the effect of OCA on all-cause mortality and liver-related clinical outcomes, as well as long-term safety.


About Ocaliva® (obeticholic acid)


Ocaliva is indicated in the United States for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.


This indication is approved under the accelerated approval pathway based on a reduction in alkaline phosphatase (ALP) as a surrogate endpoint which is reasonably likely to predict clinical benefit, including an improvement in liver transplant free-survival. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. We are conducting a Phase 4 clinical outcomes trial, which we refer to as our COBALT trial, of OCA in patients with PBC with the goal of confirming clinical benefit on a post-marketing basis.





In December 2016, Ocaliva received conditional marketing authorization in Europe for the treatment of PBC in combination with UDCA in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA, conditioned upon us providing further data post-approval to confirm benefit. For detailed safety information for Ocaliva 5 mg and 10 mg tablets including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European Summary of Product Characteristics that can be found on www.ema.europa.eu.






·Hepatic decompensation and failure, sometimes fatal or resulting in liver transplant, have been reported with OCALIVA treatment in primary biliary cholangitis (PBC) patients with either compensated or decompensated cirrhosis.
·OCALIVA is contraindicated in PBC patients with decompensated cirrhosis, a prior decompensation event, or with compensated cirrhosis who have evidence of portal hypertension.
·Permanently discontinue OCALIVA in patients who develop laboratory or clinical evidence of hepatic decompensation; have compensated cirrhosis and develop evidence of portal hypertension, or experience clinically significant hepatic adverse reactions while on treatment.




OCALIVA is contraindicated in patients with:


·decompensated cirrhosis (e.g., Child-Pugh Class B or C) or a prior decompensation event
·compensated cirrhosis who have evidence of portal hypertension (e.g., ascites, gastroesophageal varices, persistent thrombocytopenia)
·complete biliary obstruction


Warnings and Precautions


Hepatic Decompensation and Failure in PBC Patients with Cirrhosis


Hepatic decompensation and failure, sometimes fatal or resulting in liver transplant, have been reported with OCALIVA treatment in PBC patients with cirrhosis, either compensated or decompensated. Among postmarketing cases reporting it, median time to hepatic decompensation (e.g. new onset ascites) was 4 months for patients with compensated cirrhosis; median time to a new decompensation event (e.g. hepatic encephalopathy) was 2.5 months for patients with decompensated cirrhosis.


Some of these cases occurred in patients with decompensated cirrhosis when they were treated with higher than the recommended dosage for that patient population; however, cases of hepatic decompensation and failure have continued to be reported in patients with decompensated cirrhosis even when they received the recommended dosage.





Hepatotoxicity was observed in the OCALIVA clinical trials. A dose-response relationship was observed for the occurrence of hepatic adverse reactions including jaundice, worsening ascites, and primary biliary cholangitis flare with dosages of OCALIVA of 10 mg once daily to 50 mg once daily (up to 5-times the highest recommended dosage), as early as one month after starting treatment with OCALIVA in two 3-month, placebo-controlled clinical trials in patients with primarily early stage PBC.


Routinely monitor patients for progression of PBC, including hepatic adverse reactions, with laboratory and clinical assessments to determine whether drug discontinuation is needed. Closely monitor patients with compensated cirrhosis, concomitant hepatic disease (e.g., autoimmune hepatitis, alcoholic liver disease), and/or with severe intercurrent illness for new evidence of portal hypertension (e.g., ascites, gastroesophageal varices, persistent thrombocytopenia), or increases above the upper limit of normal in total bilirubin, direct bilirubin, or prothrombin time to determine whether drug discontinuation is needed. Permanently discontinue OCALIVA in patients who develop laboratory or clinical evidence of hepatic decompensation (e.g., ascites, jaundice, variceal bleeding, hepatic encephalopathy), have compensated cirrhosis and develop evidence of portal hypertension (e.g., ascites, gastroesophageal varices, persistent thrombocytopenia), experience clinically significant hepatic adverse reactions, or develop complete biliary obstruction. If severe incurrent illness occurs, interrupt treatment with OCALIVA and monitor the patient’s liver function. After resolution of the intercurrent illness, consider the potential risks and benefits of restarting OCALIVA treatment.


Severe Pruritus


Severe pruritus was reported in 23% of patients in the OCALIVA 10 mg arm, 19% of patients in the OCALIVA titration arm, and 7% of patients in the placebo arm in a 12-month double-blind randomized controlled clinical trial of 216 patients. Severe pruritus was defined as intense or widespread itching, interfering with activities of daily living, or causing severe sleep disturbance, or intolerable discomfort, and typically requiring medical interventions. Consider clinical evaluation of patients with new onset or worsening severe pruritus. Management strategies include the addition of bile acid binding resins or antihistamines, OCALIVA dosage reduction, and/or temporary interruption of OCALIVA dosing.


Reduction in HDL-C


Patients with PBC generally exhibit hyperlipidemia characterized by a significant elevation in total cholesterol primarily due to increased levels of high-density lipoprotein-cholesterol (HDL-C). Dose-dependent reductions from baseline in mean HDL-C levels were observed at 2 weeks in OCALIVA-treated patients, 20% and 9% in the 10 mg and titration arms, respectively, compared to 2% in the placebo arm. Monitor patients for changes in serum lipid levels during treatment. For patients who do not respond to OCALIVA after 1 year at the highest recommended dosage that can be tolerated (maximum of 10 mg once daily), and who experience a reduction in HDL-C, weigh the potential risks against the benefits of continuing treatment.


Adverse Reactions


The most common adverse reactions (≥5%) are: pruritus, fatigue, abdominal pain and discomfort, rash, oropharyngeal pain, dizziness, constipation, arthralgia, thyroid function abnormality, and eczema.


Drug Interactions


·Bile Acid Binding Resins
Bile acid binding resins such as cholestyramine, colestipol, or colesevelam adsorb and reduce bile acid absorption and may reduce the absorption, systemic exposure, and efficacy of OCALIVA. If taking a bile acid binding resin, take OCALIVA at least 4 hours before or 4 hours after taking the bile acid binding resin, or at as great an interval as possible.





The International Normalized Ratio (INR) decreased following coadministration of warfarin and OCALIVA. Monitor INR and adjust the dose of warfarin, as needed, to maintain the target INR range when co-administering OCALIVA and warfarin.


·CYP1A2 Substrates with Narrow Therapeutic Index
Obeticholic acid may increase the exposure to concomitant drugs that are CYP1A2 substrates. Therapeutic monitoring of CYP1A2 substrates with a narrow therapeutic index (e.g., theophylline and tizanidine) is recommended when co-administered with OCALIVA.


·Inhibitors of Bile Salt Efflux Pump
Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP) such as cyclosporine. Concomitant medications that inhibit canalicular membrane bile acid transporters such as the BSEP may exacerbate accumulation of conjugated bile salts including taurine conjugate of obeticholic acid in the liver and result in clinical symptoms. If concomitant use is deemed necessary, monitor serum transaminases and bilirubin.


Please click here for Full Prescribing Information, including Boxed WARNING.


To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


Cautionary Note Regarding Forward-Looking Statements


This press release contains forward-looking statements, including, but not limited to, statements regarding the progress, timing and results of our clinical trials, including our clinical trials for the treatment of nonalcoholic steatohepatitis (“NASH”), the safety and efficacy of our approved product, Ocaliva (obeticholic acid or “OCA”) for primary biliary cholangitis (“PBC”), and our product candidates, including OCA for liver fibrosis due to NASH, the timing and acceptance of our regulatory filings and the potential approval of OCA for liver fibrosis due to NASH, the review of our New Drug Application for OCA for the treatment of liver fibrosis due to NASH by the U.S. Food and Drug Administration (FDA), our intent to work with the FDA to address the issues raised in the complete response letter (CRL), the potential commercial success of OCA, as well as our strategy, future operations, future financial position, future revenue, projected costs, financial guidance, prospects, plans and objectives.






These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “possible,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement except as required by law. These forward-looking statements are based on estimates and assumptions by our management that, although believed to be reasonable, are inherently uncertain and subject to a number of risks. The following represent some, but not necessarily all, of the factors that could cause actual results to differ materially from historical results or those anticipated or predicted by our forward-looking statements: our ability to successfully commercialize Ocaliva for PBC; our ability to maintain our regulatory approval of Ocaliva for PBC in the United States, Europe, Canada, Israel, Australia and other jurisdictions in which we have or may receive marketing authorization; our ability to timely and cost-effectively file for and obtain regulatory approval of our product candidates on an accelerated basis or at all, including OCA for liver fibrosis due to NASH following the issuance of the CRL by the FDA; any advisory committee recommendation or dispute resolution determination that our product candidates, including OCA for liver fibrosis due to NASH, should not be approved or approved only under certain conditions; any future determination that the regulatory applications and subsequent information we submit for our product candidates, including OCA for liver fibrosis due to NASH, do not contain adequate clinical or other data or meet applicable regulatory requirements for approval; conditions that may be imposed by regulatory authorities on our marketing approvals for our products and product candidates, including OCA for liver fibrosis due to NASH, such as the need for clinical outcomes data (and not just results based on achievement of a surrogate endpoint), any risk mitigation programs such as a REMS, and any related restrictions, limitations and/or warnings contained in the label of any of our products or product candidates; any potential side effects associated with Ocaliva for PBC, OCA for liver fibrosis due to NASH or our other product candidates that could delay or prevent approval, require that an approved product be taken off the market, require the inclusion of safety warnings or precautions, or otherwise limit the sale of such product or product candidate, including in connection with our update to Ocaliva prescribing information announced in May 2021 contraindicating Ocaliva for patients with PBC and decompensated cirrhosis, a prior decompensation event, or compensated cirrhosis with evidence of portal hypertension; the initiation, timing, cost, conduct, progress and results of our research and development activities, preclinical studies and clinical trials, including any issues, delays or failures in identifying patients, enrolling patients, treating patients, retaining patients, meeting specific endpoints in the jurisdictions in which we intend to seek approval or completing and timely reporting the results of our NASH or PBC clinical trials; the outcomes of interactions with regulators (e.g., the FDA and the European Medicines Agency) regarding our clinical trials; our ability to establish and maintain relationships with, and the performance of, third-party manufacturers, contract research organizations and other vendors upon whom we are substantially dependent for, among other things, the manufacture and supply of our products, including Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH, and our clinical trial activities; our ability to identify, develop and successfully commercialize our products and product candidates, including our ability to successfully launch OCA for liver fibrosis due to NASH, if approved; our ability to obtain and maintain intellectual property protection for our products and product candidates, including our ability to cost-effectively file, prosecute, defend and enforce any patent claims or other intellectual property rights; the size and growth of the markets for our products and product candidates and our ability to serve those markets; the degree of market acceptance of Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH or our other product candidates among physicians, patients and healthcare payors; the availability of adequate coverage and reimbursement from governmental and private healthcare payors for our products, including Ocaliva for PBC and, if approved, OCA for liver fibrosis due to NASH, and our ability to obtain adequate pricing for such products; our ability to establish and maintain effective sales, marketing and distribution capabilities, either directly or through collaborations with third parties; competition from existing drugs or new drugs that become available; our ability to attract and retain key personnel to manage our business effectively; our ability to prevent system failures, data breaches or violations of data protection laws; costs and outcomes relating to any disputes, governmental inquiries or investigations, regulatory proceedings, legal proceedings or litigation, including any securities, intellectual property, employment, product liability or other litigation; our collaborators’ election to pursue research, development and commercialization activities, including joint research based on our current partnership agreements; our ability to establish and maintain relationships with collaborators with development, regulatory and commercialization expertise; our need for and ability to generate or obtain additional financing; our estimates regarding future expenses, revenues and capital requirements and the accuracy thereof; our use of cash, cash equivalents and short-term investments; our ability to acquire, license and invest in businesses, technologies, product candidates and products; our ability to manage the growth of our operations, infrastructure, personnel, systems and controls; our ability to obtain and maintain adequate insurance coverage; continuing threats from COVID-19, including additional waves of infections, and their impacts including quarantines and other government actions, delays relating to our regulatory applications, disruptions relating to our ongoing clinical trials or involving our contract research organizations, study sites or other clinical partners, disruptions relating to our supply chain or involving our third-party manufacturers, distributors or other distribution partners, and facility closures or other restrictions, and impact of the foregoing on our results of operations and financial position; the impact of general U.S. and foreign economic, industry, market, regulatory or political conditions, including the impact of Brexit; and the other risks and uncertainties identified in our periodic filings filed with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2020.









For more information about Intercept, please contact:


Caileigh Dougherty



Christopher Frates







Intercept Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations


(In thousands, except per share data)




   Three Months Ended
June 30,
   Six Months Ended
June 30,
   2021   2020   2021   2020 
Product revenue, net  $96,576   $77,249   $178,237   $149,901 
Total revenue   96,576    77,249    178,237    149,901 
Operating expenses:                    
Cost of sales   618    1,877    1,428    2,729 
Selling, general and administrative   57,655    93,360    161,926    191,918 
Research and development   37,792    34,042    88,558    90,729 
Restructuring   (249)   -    (88)   - 
Total operating expenses   95,816    129,279    206,824    285,376 
Operating income (loss)   760    (52,030)   (28,587)   (135,475)
Other income (expense):                    
Interest expense   (12,589)   (11,933)   (25,008)   (23,710)
Other income, net   735    682    2,081    2,921 
    (11,854)   (11,251)   (22,927)   (20,789)
Net loss  $(11,094)  $(63,281)  $(51,514)  $(156,264)
Net loss per common and potential common share:                    
Basic and diluted  $(0.33)  $(1.92)  $(1.55)  $(4.74)
Weighted average common and potential common shares outstanding:                    
Basic and diluted   33,179    32,960    33,159    32,941 



Condensed Consolidated Balance Sheet Information

(In thousands)


   June 30,
   December 31,
2020 (1)
Cash, cash equivalents, restricted cash and investment debt securities, available for sale  $422,480   $477,170 
Total assets  $523,224   $580,489 
Total liabilities (2)  $726,419   $747,342 
Stockholders’ deficit  $(203,195)  $(166,853)



(1)Derived from the audited financial statements included in Intercept’s Annual Report on Form 10-K for the year ended December 31, 2020.


(2)Includes $575.8 million and $560.6 million related to the 2023 Convertible Notes and the 2026 Convertible Notes (together, the “Convertible Notes”) as of June 30, 2021 and December 31, 2020, respectively. Intercept separately accounts for the debt and equity components of the Convertible Notes. The aggregate outstanding principal amount of the Convertible Notes was $690.0 million as of June 30, 2021, and December 31, 2020.





Reconciliation of Non-GAAP Adjusted Operating Expenses to Total Operating Expenses


(In thousands)


   Three Months Ended
June 30,
   Six Months Ended
June 30,
   2021   2020   2021   2020 
Total operating expenses  $95,816   $129,279   $206,824   $285,376 
Stock-based compensation   8,448    16,083    16,867    28,556 
Depreciation   879    808    1,749    1,572 
Non-GAAP adjusted operating expenses  $86,489   $112,388   $188,208   $255,248 



EX-101.SCH 3 icpt-20210729.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 icpt-20210729_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 icpt-20210729_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image_002.jpg GRAPHIC begin 644 image_002.jpg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tm2123441d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001270073 2021-07-29 2021-07-29 iso4217:USD shares iso4217:USD shares 0001270073 false 8-K 2021-07-29 Intercept Pharmaceuticals, Inc. DE 001-35668 22-3868459 10 Hudson Yards 37th Floor New York NY 10001 646 747-1000 false false false false Common Stock, par value $0.001 per share ICPT NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Jul. 29, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 29, 2021
Entity File Number 001-35668
Entity Registrant Name Intercept Pharmaceuticals, Inc.
Entity Central Index Key 0001270073
Entity Tax Identification Number 22-3868459
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 10 Hudson Yards
Entity Address, Address Line Two 37th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10001
City Area Code 646
Local Phone Number 747-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ICPT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://interceptpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2123441d1_8k.htm icpt-20210729.xsd icpt-20210729_lab.xml icpt-20210729_pre.xml tm2123441d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2123441d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2123441d1_8k.htm" ] }, "labelLink": { "local": [ "icpt-20210729_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "icpt-20210729_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "icpt-20210729.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "icpt", "nsuri": "http://interceptpharma.com/20210729", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2123441d1_8k.htm", "contextRef": "From2021-07-29to2021-07-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://interceptpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2123441d1_8k.htm", "contextRef": "From2021-07-29to2021-07-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-097249-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-097249-xbrl.zip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end